Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2005 by East Valley Hematology and Oncology Medical Group.
Recruitment status was  Recruiting
Mena, Raul, M.D.
Pharmatech Oncology
Astex Pharmaceuticals
Information provided by:
East Valley Hematology and Oncology Medical Group Identifier:
First received: August 16, 2005
Last updated: August 17, 2005
Last verified: August 2005
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: April 2009
  Estimated Primary Completion Date: No date given